BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...
DexCom (NASDAQ:DXCM – Get Free Report) had its price objective increased by research analysts at Barclays from $90.00 to $93.00 in a report issued on Monday,Benzinga reports. The brokerage presently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback